Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of AR124661A2publicationCriticalpatent/AR124661A2/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Una composición farmacéutica sólida adecuada para su administración oral, la cual comprende: (a) un modulador del receptor S1P; (b) un relleno, y (c) una ciclodextrina. Reivindicación 1: Una composición farmacéutica sólida adecuada para su administración oral, la cual comprende: a) un primer compuesto seleccionado a partir de 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol, una sal farmacéuticamente aceptable del mismo, y un derivado de fosfato del mismo, b) un relleno, y c) un estabilizante que comprende una ciclodextrina o un derivado de la misma. Reivindicación 9: Una composición de acuerdo con cualquiera de las reivindicaciones anteriores, para el tratamiento de una enfermedad autoinmune.A solid pharmaceutical composition suitable for oral administration, which comprises: (a) an S1P receptor modulator; (b) a filler, and (c) a cyclodextrin. Claim 1: A solid pharmaceutical composition suitable for oral administration, which comprises: a) a first compound selected from 2-amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1, 3-diol, a pharmaceutically acceptable salt thereof, and a phosphate derivative thereof, b) a filler, and c) a stabilizer comprising a cyclodextrin or derivative thereof. Claim 9: A composition according to any of the preceding claims, for the treatment of an autoimmune disease.
solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d and process for obtaining said composition
Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4 -methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-i soindol-4-yl}-amidecelgene corporation state of incorporation:delaware.